

## *RNA Interference*

Diane Carrera  
MacMillan Group Meeting  
January 21, 2009

### **Lead References:**

Nobel Lectures: Fire, A. Z. *Angew. Chem., Int. Ed.* **2007**, 46, 6966  
Mello, C. C. *Angew. Chem., Int. Ed.* **2007**, 46, 6985  
*Nature* Insight: *Nature* **2004**, 431, 338

# *Overview*

## ■ Introduction to RNAi

- What is it?
- Why should we care about RNAi?
- Biochem Basics

## ■ Discovery of RNAi

## ■ Elucidation of RNAi Mechanism


- Identifying RISC components
- Other RNAi triggers

## ■ RNAi and Chromatin Modification

## ■ Possible Therapeutic Applications

## What is RNA Interference?

- RNA interference(RNAi) is the knockdown of gene expression by small RNA fragments



- 1998 – Mello and Fire publish a seminal *Nature* paper elucidating the trigger for the RNAi process
- 2006 – Mello and Fire awarded Nobel Prize in Physiology and Medicine

Andrew Fire  
Stanford




Craig Mello  
UMass



# Why is RNAi Important?


## ■ Provides valuable insight into evolution

- found in all eukaryotes except some fungi  $\Rightarrow$  ancient biochemical mechanism
- the original form of cellular immunity, signal can also spread horizontally and vertically



- indicates that gene expression is the key to evolving complex organisms

Human



protein encoding genes  
miRNAs

$21 \times 10^3$   
677




Nematode


$19 \times 10^3$   
154



## Why is RNAi Important?

### ■ Invaluable tool for functional genomics

- Knockdowns are easier than knockouts  Saves time and money
- Allows for study of function with a variety of controls: positive, negative, rescue



- Many public databases (UPenn, Cold Spring Harbor, MIT) now exist for the design of interfering RNAs to target specific genes

### ■ Medicine and Biotech




*Science* "Breakthrough of the Year" 2002

*Fortune* "Billion Dollar Breakthrough"




## Basic Biochem

- DNA and RNA are information containing biopolymers



## Basic Biochem

- DNA and RNA are information containing biopolymers





backbone: ribose

prone to hydrolysis



short term  
information storage



backbone: deoxyribose

stable to hydrolysis





long term  
information storage

# Basics of Gene Expression

## ■ Gene Expression is comprised of Transcription & Translation with distinct roles for DNA & RNA


- DNA: the architect with the master set of blueprints
- RNA: the contractor overseeing specific tasks




# Transcription

■ Transcription is the transfer of information from DNA to messenger RNA (mRNA) and has 3 distinct stages


**Initiation:** RNA polymerase enzyme (RNAP) inserts into DNA double helix




**Elongation:** RNAP builds a strand of mRNA from the template DNA strand



**Termination:** mRNA synthesis is complete, RNAP and mRNA are released into solution and double helix reforms




RNAP: 2006 Nobel Prize in Chemistry, Roger Kornberg



# Translation


■ Translation is the synthesis of proteins in 4 distinct stages using the mRNA template

**4. Termination:** peptide released upon reaching stop codon (UAA, UAG, UGA)



**3. Elongation:** peptide chain grows as amino acids are brought in by tRNAs with anticodons corresponding to mRNA codons


**2. Initiation:** small subunit of ribosome binds 5' end of mRNA



**1. Activation:** amino acids bind to transfer RNA (tRNA)

## The Biochemist's Best Friend

- *Caenorhabditis elegans* (*C. elegans*) is an ideal system for studying gene expression



- nematode roundworm
- 1mm in length
- lives in soil




the developmental timeline of every cell has been mapped

phenotypic response to gene expression is well defined

<i>unc-22</i> repression	→	twitching
<i>par-1</i> repression	→	symmetrical cell division

- Microinjection technique allows for the direct introduction of macromolecules into the animal




- ability to affect large populations
- RNA, DNA and proteins can all be injected



## Unexplained Results with Antisense


- In the 1990's, antisense looks like the next big thing

### antisense mediated silencing



- Some experiments are giving unexpected results

### Guo & Kemphues discover that both sense and antisense strands mediate silencing



*Cell* **1995**, 81, 611


antisense experiments with *unc-22* give same result  
suppression effects persist and are passed on through germline

*Fire Development* **1991**, 113, 503  
*Kuwabara Genetics* **1996**, 144, 597





## Finding the Trigger

- Electrophoresis shows RNA preparations are contaminated with dsRNA



## A Very Potent Trigger

- Dilution studies show supression is obtained with as little as a few molecules per cell



### Progeny cohort group


- 0-6 h
- 6-15 h
- 15-27 h
- 27-41 h
- 41-56 h

suppression of *unc-22* occurs with small amounts of dsRNA


## Vital Control Experiments

- Control experiments reveal dsRNA interference is gene specific and spreads throughout the worm cells

complex RNA



microinjection




dsRNA mediated interference is specific

GFPG - mitochondrial gfp  
LACZ - nuclear gfp



non-striated muscles are only unaffected cells




## RNAi: So Easy a First Year Can Do It

- Injection into gonads is not required for RNAi to be effective

improperly placed needles still lead to interference

dsRNA	Injection Site	Phenotype	Progeny Phenotype
none	gonad or cavity	no twitching strong GFP	no twitching strong GFP
<i>unc22</i>	gonad body-cavity	weak twitchers weak twitchers	strong twitchers strong twitchers
<i>gfpG</i>	gonad body-cavity	weak GFP weak GFP	absent GFP absent GFP
<i>lacZL</i>	gonad body cavity	weak nuclear GFP weak nuclear GFP	absent nuclear GFP absent nuclear GFP

- Ingestion of dsRNA expressing *E. coli* and soaking also work



"Do experiments that your advisor would never condone or suggest" – Fire, Nobel lecture



Timmons, Fire *Nature* **1998**, 395, 854  
Mello *Science*, **1998**, 282, 430

## What's in the Black Box?

- Early experiments reveal target mRNA degradation is initiated by dsRNA


*mex-3* mRNA can be detected by staining

**negative control**  
no staining in wild type  
without hybridization



**positive control**  
staining in wild type  
with hybridization

*mex-3* antisense RNA



*mex-3* dsRNA



dsRNA




degraded mRNA

## What's in the Black Box?

- A clever experiment reveals which genes are involved in RNAi

*pos-1* expression is required for *C. elegans* survival



Fire, Mello *Cell* **1999**, 99, 123

- *Rde-1* identified as a member of the little known argonaute family of proteins

# What's in the Black Box?

- Two groups take the lead in working out the RNAi biochemical pathway

*Nature* **1998**, 391, 806

Mello & Fire  
establish dsRNA  
as trigger for RNAi

*Nature* **2000**, 404, 293

Hannon defines RISC  
complex as cause of  
mRNA degradation

*Cell* **2000**, 101, 25

Tuschl & Sharp find  
mRNA is cleaved into 22  
nt fragments



**Greg Hannon**  
Cold Spring Harbor

1998

2000

1999

2001

Sharp & Tuschl  
replicate RNAi in vitro


*Genes Dev.* **1999**, 13, 3191

Hannon defines roles of  
Dicer & Slicer, identifies  
Argonaute in RISC

*Nature* **2001**, 409, 363  
*Science* **2001**, 293, 1146

Tuschl determines  
structures of Dicer  
dsRNA products, siRNA

*Gene Dev.* **2001**, 15, 188  
*Nature* **2001**, 411, 494




**Phil Sharp**  
MIT



**Thomas Tuschl**  
MIT, Gottingen, Rockefeller


# Overall Scheme of RNAi process






# Crystal Structure Reveals Dicer Mechanism

■ Doudna *et. al.* is able to obtain a crystal structure of *G. intestinalis* Dicer enzyme




Dicing requires both enzyme and  $Mg^{2+}$  to produce siRNAs 25-27 nt in length




contains dsRNA binding PAZ domain

Glu and Asp perform cleavage in active site




two RNase III domains



A distance of 17.5 Å between the RNase III domains fits the width of the major groove of dsRNA

## Crystal Structure Reveals Dicer Mechanism

- Analysis reveals Dicer is in effect a molecular ruler



A distance of 65 Å between the PAZ and RNase III domains corresponds to the length of an siRNA fragment containing 25 bp

3' two nucleotide overhang recognition by PAZ OB fold is conserved across many species

# Crystal Structure of Argonaute Reveals Slicer Mechanism



- Argonaute has been closely linked to RNAi across all species studied

As seen with Dicer, Slicer also requires  $Mg^{2+}$  for activity



positively charged groove in crescent formed between base (N-terminal, middle and PIWI domains) and overhanging PAZ domain

⇒ phosphate binding






# Crystal Structure of Argonaute Reveals Slicer Mechanism

- Modelling of siRNA guide strand and mRNA places scissile bond in active site


B




PAZ binds phosphate between 2 overhanging nucleotides of guide strand via H-bonding with His & Tyr residues

human Ago1

Pf Ago



evidence for binding 5' end with PIWI and/or middle domain





Leemor Joshua-Tor  
Cold Spring Harbor

base pairing with the guide strand positions mRNA target for cleavage in PIWI domain


## RNAi is also Triggered by microRNAs

- Ambros discovers the first endogenous short RNA (microRNA) via forward genetics in 1993





miRNAs use the RNAi pathway to regulate gene expression, controlling cell development throughout animal life cycles

*c-myc* overexpression → lymphoma



## miRNAs Are Correlated with Complexity

- miRNAs are found in all animals and attempts to find all miRNA encoding genes are ongoing



**Bartel proposes miRNA regulation could explain why complex organisms have the same number of genes as simple ones**


*Nature*, 2008, 455, 1193

gene regulation  $\Rightarrow$  evolution


## *RNAi Also Directs Heterochromatin Formation*

■ Discovered in 1928, heterochromatin is darkly staining, covalently modified chromatin that does not unwind at any time in the cell cycle

has a regulatory effect on nearby genes,  
ie fruitfly & maize variegation




comprised of short repeating sequences,  
heterochromatin produces repeat associated  
siRNAs (rasiRNAs) that induce covalent  
modification of DNA & histone



## RNAi Also Directs Heterochromatin Formation

- Though its exact mechanism is still unclear, the RNA-induced transcriptional silencing (RITS) complex plays the role of RISC and contains an argonaute protein

Joshua-Tor *Nature Chemical Biology* 2006, 3, 36



chromatin modification



inherited gene regulation




evolution




## Therapeutic Possibilities for RNAi

- Using RNAi as an experimental and therapeutic tool requires several considerations

**Innate immune response (interferon) provides viral immunity**



**Design of siRNA**



- strand with lower 5' thermodynamic stability (A–T) is incorporated into RISC
- seed region has greatest effect on mRNA recognition
- cleavage site between nt 10 & 11 from 5' end

### 4 Rules for effective siRNAs



1. Get right strand into RISC (design algorithms)
2. Target several alleles (phenotypic correlation)
3. Use low concentrations (limit off target effects)
4. Use rescue experiments (important control)

## Therapeutic Possibilities for RNAi

- Endogenous miRNAs have inspired the design of short hairpin RNAs (shRNAs)



synthetic DNA



shRNA

**advantage:** longer lasting suppression,  
easy delivery

**disadvantage:** need to design DNA  
construct

HIV

- RNAi has been demonstrated to stop spread of HIV in mice
- high mutation rate poses problems, cellular cofactors are other possible targets (NF- $\kappa$ B, CD4, CXCR4, CCR5)

Hepatitis C

- blocking has been demonstrated but it is temporary due to virus mutation

Cancer

- Alnylam compound in clinical trials for treatment of liver cancer
- contains 2 siRNAs in lipid nanoparticle (Tekmira) targeting KSP & VEGF

Genetic  
Disease

- Amyotrophic lateral sclerosis treatment targeting single nucleotide mutant of *sod1*
- Huntingtons disease

## Therapeutic Possibilities for RNAi

- The path to commercial therapies that utilize RNAi is not necessarily clear

### Can the RNAi pathway be saturated?


- therapies hijack the native RNAi machinery which we know is used in gene expression
- RISC saturation has been shown *in vitro*

### How can we delivery these therapies?

- this issue has plagued antisense for over 20 years
- many options exist (backbone modification, virus vectors, transfection) but none work perfectly
- for now targets are set low (liver)

### What about off target effects?

- suppression of cofactors may result in disruption of normal cellular processes
- chromatin modification has not yet been identified in humans but endogenous RNAs point to the possibility of its existence



## *Conclusions*

■ RNAi is an important part of the cellular machinery that provides viral immunity and a mechanism for the control of gene expression

■ A variety of RNA triggers function in the RNAi mechanism result in gene suppression that can be both temporary and permanent

dsRNA, siRNA, miRNA, shRNA

■ Recent studies have implied that RNAi could be an important factor in evolution due to its key role in epigenetics


miRNA, chromatin modification

■ Potential therapeutic applications of RNAi include treatments for viruses, cancer and heritable disease

■ The field is relatively young and much remains to be discovered

## RNAi is Actually Quite Complicated

- RNAi is still an emerging field with many unanswered questions and potential applications



*C. elegans* contains 27 argonaute proteins, all of which are involved in RNAi